These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 22006914)

  • 1. Plasma levels of metabolites of catecholamine in nicotine-dependent patients treated with varenicline.
    Umene-Nakano W; Yoshimura R; Yoshii C; Hayashi K; Ikenouchi-Sugita A; Katsuki A; Hori H; Nakamura J
    Nicotine Tob Res; 2012 Apr; 14(4):486-9. PubMed ID: 22006914
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Varenicline does not increase serum BDNF levels in patients with nicotine dependence.
    Umene-Nakano W; Yoshimura R; Yoshii C; Hoshuyama T; Hayashi K; Hori H; Katsuki A; Ikenouchi-Sugita A; Nakamura J
    Hum Psychopharmacol; 2010 Apr; 25(3):276-9. PubMed ID: 20373480
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness.
    Stapleton JA; Watson L; Spirling LI; Smith R; Milbrandt A; Ratcliffe M; Sutherland G
    Addiction; 2008 Jan; 103(1):146-54. PubMed ID: 18028247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nicotine gum dependence treated with varenicline--a case report.
    Garelik DA
    Nicotine Tob Res; 2010 Oct; 12(10):1041-2. PubMed ID: 20829327
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up.
    Nides M; Oncken C; Gonzales D; Rennard S; Watsky EJ; Anziano R; Reeves KR
    Arch Intern Med; 2006 Aug 14-28; 166(15):1561-8. PubMed ID: 16908788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Varenicline for smokeless tobacco dependence.
    Aggarwal A; Jain M; Jiloha RC
    J Postgrad Med; 2010; 56(1):50. PubMed ID: 20393259
    [No Abstract]   [Full Text] [Related]  

  • 7. Varenicline for tobacco dependence.
    Hays JT; Ebbert JO
    N Engl J Med; 2008 Nov; 359(19):2018-24. PubMed ID: 18987369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of the novel selective nicotinic acetylcholine receptor partial agonist, varenicline, for smoking cessation.
    Oncken C; Gonzales D; Nides M; Rennard S; Watsky E; Billing CB; Anziano R; Reeves K
    Arch Intern Med; 2006 Aug 14-28; 166(15):1571-7. PubMed ID: 16908789
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of varenicline on smoking cessation in adults with stably treated current or past major depression: a randomized trial.
    Anthenelli RM; Morris C; Ramey TS; Dubrava SJ; Tsilkos K; Russ C; Yunis C
    Ann Intern Med; 2013 Sep; 159(6):390-400. PubMed ID: 24042367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reproducibility of plasma catecholamine metabolites in normal subjects.
    Amin F; Hashmi A; Stroe AE; Adebogun O; Densmore D; Knott PJ
    Biol Psychiatry; 1998 Feb; 43(3):233-5. PubMed ID: 9494706
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced affective symptoms during tobacco dependence treatment with varenicline.
    Grosshans M; Mutschler J; Hermann D; Mann K; Diehl A
    Addiction; 2009 May; 104(5):859-61. PubMed ID: 19413797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tobacco dependence treatment for hospitalized smokers: a randomized, controlled, pilot trial using varenicline.
    Steinberg MB; Randall J; Greenhaus S; Schmelzer AC; Richardson DL; Carson JL
    Addict Behav; 2011 Dec; 36(12):1127-32. PubMed ID: 21835552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Fagerström Test for Nicotine Dependence as a predictor of smoking abstinence: a pooled analysis of varenicline clinical trial data.
    Fagerström K; Russ C; Yu CR; Yunis C; Foulds J
    Nicotine Tob Res; 2012 Dec; 14(12):1467-73. PubMed ID: 22467778
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A double-blind randomized placebo-controlled pilot study of neuropsychiatric adverse events in abstinent smokers treated with varenicline or placebo.
    Garza D; Murphy M; Tseng LJ; Riordan HJ; Chatterjee A
    Biol Psychiatry; 2011 Jun; 69(11):1075-82. PubMed ID: 21295286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Varenicline treatment of concurrent alcohol and nicotine dependence in schizophrenia: a randomized, placebo-controlled pilot trial.
    Meszaros ZS; Abdul-Malak Y; Dimmock JA; Wang D; Ajagbe TO; Batki SL
    J Clin Psychopharmacol; 2013 Apr; 33(2):243-7. PubMed ID: 23422399
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neurobiological basis for partial agonist treatment of nicotine dependence: varenicline.
    Foulds J
    Int J Clin Pract; 2006 May; 60(5):571-6. PubMed ID: 16700857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effectiveness and safety of varenicline for smoking cessation].
    Christalla P; Dewenter M; El-Armouche A
    Dtsch Med Wochenschr; 2012 May; 137(18):940-4. PubMed ID: 22492478
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characteristics and abstinence outcomes among tobacco quitline enrollees using varenicline or nicotine replacement therapy.
    Biazzo LL; Froshaug DB; Harwell TS; Beck HN; Haugland C; Campbell SL; Helgerson SD
    Nicotine Tob Res; 2010 Jun; 12(6):567-73. PubMed ID: 20378640
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of varenicline, nicotine or placebo on depressive symptoms in postmenopausal smokers.
    Avery N; Kenny AM; Kleppinger A; Brindisi J; Litt MD; Oncken CA
    Am J Addict; 2014; 23(5):459-65. PubMed ID: 24628943
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Varenicline for tobacco dependence.
    Cantrell MA; Geraets D
    N Engl J Med; 2009 Feb; 360(7):730-1. PubMed ID: 19213691
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.